Prab: CSV import

2025-02-13T03:30:26Z

CSV import

@@ Line 1: / Line 1: @@
-{{intro}}
+== Enfuvirtide ==
-{{livtox}}
+[[File:Enfuvirtide.svg|thumb|right|Chemical structure of Enfuvirtide]]
-{{moa}}
+'''Enfuvirtide''' is an [[antiretroviral drug]] used in the treatment of [[HIV/AIDS]]. It is classified as a [[fusion inhibitor]], which means it prevents the [[HIV]] virus from entering human cells. Enfuvirtide is marketed under the brand name '''Fuzeon'''.
-{{fda}}
+== Mechanism of Action ==
-{{se}}
+Enfuvirtide works by binding to the [[gp41]] subunit of the [[HIV envelope glycoprotein]]. This binding prevents the conformational changes required for the fusion of the viral and cellular membranes, thereby inhibiting the entry of the virus into the host [[CD4+ T cells]].
-The only common side effects specifically linked to enfuvirtide have been injection site reactions (which can be troublesome) and eosinophilia. Regimens that include enfuvirtide have the potential to cause immune reconstitution syndrome, pneumonitis and severe hypersensivity reactions.
-{{antiviral agents}}
+== Administration ==
-{{coststubd}}

Prab: Created page with "{{intro}} Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). {{livtox}} Enfuvirtide has..."

2019-05-01T09:12:16Z

Created page with "{{intro}} Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). {{livtox}} Enfuvirtide has..."

New page

{{intro}}
Enfuvirtide is an [[HIV]] fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus ([[HIV]]).

{{livtox}}
Enfuvirtide has not been associated with serum [[aminotransferase]] elevations during therapy or episodes of acute, clinically apparent [[liver injury]].

{{moa}}
Enfuvirtide (en fue' vir tide) is relatively new antiretroviral drug that blocks the fusion of [[HIV]] to target cell, preventing viral entry and subsequent infection. Enfuvirtide is a 36 amino acid biomimetic peptide that resembles the [[HIV]] proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. Enfuvirtide has both in vitro and in vivo activity against [[HIV]], and several randomized controlled trials have shown that it leads to significant decline in [[HIV]] RNA levels and rises in peripheral [[CD4 T cell counts].

{{fda}}
{{PAGENAME}} was approved for use in the United States in 2003, but it has had limited use, partially because it requires parenteral administration once or twice daily. Enfuvirtide is available in single use vials that contain 90 mg/mL after reconstitution under the brand name of Fuzeon. The recommended regimen for enfuvirtide is 90 mg subcutaneously twice daily in adults and 2 mg/kg in children ages 6 to 16. Enfuvirtide is recommended only in combination with other antiretroviral agents.

{{se}}
The only common side effects specifically linked to enfuvirtide have been injection site reactions (which can be troublesome) and eosinophilia. Regimens that include enfuvirtide have the potential to cause immune reconstitution syndrome, pneumonitis and severe hypersensivity reactions.
{{antiviral agents}}
{{coststubd}}

Enfuvirtide - Revision history

Prab: CSV import

Prab: Created page with "{{intro}} Enfuvirtide is an HIV fusion inhibitor, the first of this class of agents active against the human immunodeficiency virus (HIV). {{livtox}} Enfuvirtide has..."